Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lymphoma Study Association
With
Fondation ARC
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient with diffuse large B-cell lymphoma according to the WHO classification (anti CD20 labeling)
Aged 18 to 60 years
Non previously treated
With one and only one of the following adverse characteristics: ECOG performance status 2 or more, or Ann Arbor stage III or IV, or elevated LDH level
Negative HIV, HBV and HCV serologies (except vaccination)
With a minimum life expectancy of 3 months
Having previously signed a written informed consent
You may not be if
Any history of treated or non-treated indolent lymphoma.
T-cell lymphoma.
Central nervous system or meningeal involvement by lymphoma.
Any Contra-indication to any drug contained in the chemotherapy regimens.
Poor renal function (creatinin level\>150µmol/l), poor hepatic function (total bilirubin level\>30mmol/l, transaminases\>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.
Serious active disease (according to the investigator's decision).
Poor bone marrow reserve as defined by neutrophils \<1.5G/l or platelets\<100G/l, unless related to bone marrow infiltration.
Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.
Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.
Childbearing woman.
Patients previously treated with an organ transplantation.
